Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 3/20 | 0.37 |
| ▸ | MAPK9 | P45984 | 3/20 | 0.37 |
| ▸ | CSNK1A1 | P48729 | 3/20 | 0.37 |
| ▸ | CSNK1D | P48730 | 3/20 | 0.37 |
| ▸ | MINK1 | Q8N4C8 | 3/20 | 0.37 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.37 |
| ▸ | CSNK1G3 | Q9Y6M4 | 2/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | PRKD2 | Q9BZL6 | 2/20 | 0.31 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.31 |
| ▸ | MAP4K5 | Q9Y4K4 | 1/20 | 0.31 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.31 |
| ▸ | PRKCG | P05129 | 1/20 | 0.30 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.30 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.30 |
| ▸ | GSK3B | P49841 | 1/20 | 0.30 |
| ▸ | CSNK1G2 | P78368 | 1/20 | 0.30 |
| ▸ | TAOK1 | Q7L7X3 | 1/20 | 0.30 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2869329 | 0.90 | SLC6A2 (0.32) | SLC6A2CRHR1 | |
| SCHEMBL2874015 | 0.88 | CRHR1 (0.39) | CRHR1 | |
| SCHEMBL2860920 | 0.82 | CRHR1 (0.35) | CRHR1 | |
| SCHEMBL2868097 | 0.81 | CRHR1 (0.43) | CRHR1 | |
| SCHEMBL2868190 | 0.80 | CRHR1 (0.40) | CRHR1 | |
| SCHEMBL2865995 | 0.80 | CRHR1 (0.39) | CRHR1 | |
| SCHEMBL2862167 | 0.80 | CRHR1 (0.39) | CRHR1 | |
| SCHEMBL2868182 | 0.79 | CRHR1 (0.50) | CRHR1 | |
| Hydrochloric Acid SCHEMBL2871892 | 0.78 | CRHR1 (0.49) | CRHR1 | |
| SCHEMBL2870835 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7772249-B2 | Imidazo[1,2-b]pyridazine compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-08-10 | — | — | US | disclosed |
| US-20090181985-A1 | IMIDAZO[1,2-b]PYRIDAZINE COMPOUND | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-07-16 | — | — | US | disclosed |
| US-7078405-B2 | Imidazo[1,2-b]pyridazine compound | EISAI CO., LTD. (JP) | 2006-07-18 | — | — | US | disclosed |
| US-20040082781-A1 | Bicyclic nitrogenous fused-ring compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2004-04-29 | — | — | US | disclosed |
| EP-1364952-A1 | BICYCLIC NITROGENOUS FUSED-RING COMPOUND | Eisai Co., Ltd. (JP) | 2003-11-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181985-A1 | IMIDAZO[1,2-b]PYRIDAZINE COMPOUND | CRHR1, CRHR2, CRH | MAP4K4 1018/4885MAPK9 1987/4885CSNK1A1 319/4885 |
| US-20040082781-A1 | Bicyclic nitrogenous fused-ring compound | CRHR1, CRH, CRHR2 | MAP4K4 2376/4885MAPK9 1739/4885CSNK1A1 627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.